-+ 0.00%
-+ 0.00%
-+ 0.00%

These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results

Benzinga·10/29/2026 11:30:59
Listen to the news

Boston Scientific Corp (NYSE:BSX) on Wednesday posted upbeat third-quarter financial results and cut its FY26 guidance below estimates.

The company reported Q3 revenues of $5.138 billion on Wednesday — better than the consensus estimate of $5.046 billion, but below management guidance of $5.217 billion-$5.318 billion. Adjusted earnings of 73 cents beat the consensus of 72 cents, but missed the management guidance of 80-82 cents.

Boston Scientific expects fourth-quarter adjusted earnings of 77-79 cents, below the 84-cent consensus with a Q4 sales forecast of $5.127 billion-$5.233 billion — below the consensus of $5.404 billion.

During an earnings conference call, the CEO said, "In 2026, we’ve seen that cycle turn, and those two businesses (EP and WATCHMAN franchises) are now weighing on our total company growth as we navigate competition and market dynamics."

Boston Scientific shares rose 0.5% to $42.66 in pre-market trading.

These analysts made changes to their price targets on Boston Scientific following earnings announcement.

  • BTIG analyst Marie Thibault maintained the stock with a Buy and lowered the price target from $56 to $49.
  • Baird analyst David Rescott maintained the stock with an Outperform rating and raised the price target from $50 to $51.

Considering buying BSX stock? Here’s what analysts think:

Photo via Shutterstock